Clinical trials: Daily Activities
Carcinoma, Non-Small-Cell Lung
An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)
This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety, tolerability, and maximum tolerated dose of tivozanib (AV-951) with this dosing schedule, as well as overall response rate of tivozanib…
- Trial name
- NCT00826878
- Testing
- Tivozanib (AV-951)
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Asthma, Allergies
Impact of Asthma Treatments on Daily Activities
The primary objective of this web-based, cross-sectional study is to assess and compare the ability to sleep, work or go to school, and to participate in leisure activities among subjects who are receiving Xolair treatment and…
- Trial name
- NCT00350376
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- Ovation Research Group
Stroke, Hemiparesis
Virtual Occupational Therapy Application
Virtual Occupational Therapy Application (VOTA) combines low-cost human motion tracking, commercial game engine technology, and evidence-based Occupational Therapy (OT) practice in a computer-based virtual world in which stroke…
- Trial name
- VOTA (NCT02706912)
- Testing
- VOTA Therapy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Barron Associates, Inc.
Ulcerative Colitis
Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Symptomatic Ulcerative Colitis Patients with Moderate to…
- Trial name
- TOP2 (NCT02888379)
- Testing
- TOP1288
- Where
- 28 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 77 people
- Sponsor
- Topivert Pharma Ltd
Infection, Human Immunodeficiency Virus I
48-Week Study Of GW433908 And Ritonavir Or GW433908 Alone, Twice Daily In Pediatric Patients With HIV Infection
This is a 48-week study to collect information on the safety and activity of an investigational medicine in patients, ages 2 to 18 years old, with HIV infection .
- Trial name
- NCT00089583
- Testing
- LEXIVA (GW433908), Ritonavir
- Where
- 39 sites in United States, Belgium and 5 more
- Volunteers
- 110 people
- Sponsor
- ViiV Healthcare
HIV Infections
TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) Strains
The purpose of this study is to determine the antiviral activity, safety and tolerability of 14 days of different doses of TMC114 to treat HIV-1 positive patients whose condition is failing on a current treatment regimen that…
- Trial name
- NCT00964327
- Testing
- TMC114
- Volunteers
- 42 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Asthma
Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)
This is a multicenter, randomized, double-blind, double-dummy, crossover study with two 2-week treatment periods separated by a 2-week wash-out period.
- Trial name
- NCT02730351
- Testing
- Fluticasone furoate/ Vilanterol 100 mcg/25 mcg, Fluticasone propionate 250 mcg
- Where
- 16 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Solid Tumor
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
This is a phase 1 study in which 2 to 72 patients with advanced cancer will receive oral doses of rigosertib, a new investigational (unapproved) anti-cancer drug.
- Trial name
- NCT01168011
- Testing
- rigosertib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Traws Pharma, Inc.
Essential Tremor
Continuous Tremor Assessment During Daily Activities
The specific aim of this study is to evaluate if tremor severity and quality of life can be improved more using continuous home monitoring along with traditional assessments versus traditional assessments alone.
- Trial name
- NCT01978080
- Testing
- Kinesia HomeView
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Health Behavior, Behavioral Activation
Mobile Behavioral Activation Program With Wearable Sensors and Secure Activity Verification
This study evaluates a mobile-integrated behavioral activation program designed to help adults improve their daily productivity, motivation, and task engagement.
- Conditions
- Health Behavior, Behavioral Activation, Sedentary Behavior
- Trial name
- MBAP-X (NCT07382804)
- Testing
- Behavioral: Mobile Behavioral Activation App, Mobile App + Wearable Activity Sensor, Mobile App + Wearable Sensor + Secure Activity Verification Layer
- Where
- United States
- Volunteers
- 227,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.